Kinetic interactions of tazobactam with beta-lactamases from all major structural classes
- PMID:8388201
- PMCID: PMC187782
- DOI: 10.1128/AAC.37.4.851
Kinetic interactions of tazobactam with beta-lactamases from all major structural classes
Abstract
Tazobactam was shown to be a potent inhibitor of group 1, 2a, 2b, and 2b' beta-lactamases. Extended kinetic studies with class A and C serine beta-lactamases showed that the PC1, TEM-2, and P99 enzymes all were reversibly inhibited prior to inactivation of the enzymes. The CcrA metallo-beta-lactamase was less well inhibited, with a 50% inhibitory concentration at least 3 orders of magnitude less favorable than those for most serine beta-lactamases. The numbers of hydrolytic turnovers of tazobactam before inactivation were 2 for PC1, 125 for TEM-2, 50 for P99, and 4,000 for the CcrA enzyme. In spectral studies, transient intermediates were formed after reaction of tazobactam with the PC1, TEM-2, and CcrA beta-lactamases, corresponding to enzyme-associated intermediates responsible for hydrolysis of tazobactam. Chromophores absorbing at 270 nm (CcrA) and 288 nm (TEM-2 and PC1) were observed for these reaction intermediates. The P99 cephalosporinase formed a stable complex with a UV maximum at 295 nm. Incubation of tazobactam with all of the enzymes resulted in accumulation of a tazobactam reaction product with a short-wavelength absorbance. This product has characteristics similar to those of the major eucaryotic metabolite of tazobactam. Possible reaction mechanisms are presented to explain the findings. In conclusion, both serine-based and metallo-beta-lactamases were irreversibly inactivated by tazobactam following an initial transient inhibition phase.
Similar articles
- Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.Payne DJ, Cramp R, Winstanley DJ, Knowles DJ.Payne DJ, et al.Antimicrob Agents Chemother. 1994 Apr;38(4):767-72. doi: 10.1128/AAC.38.4.767.Antimicrob Agents Chemother. 1994.PMID:8031044Free PMC article.
- Effect of clavulanic acid, sulbactam and tazobactam on three different beta-lactamases from Bacteroides uniformis, Clostridium butyricum and Fusobacterium nucleatum.Hedberg M, Lindqvist L, Tunér K, Nord CE.Hedberg M, et al.J Antimicrob Chemother. 1992 Jul;30(1):17-25. doi: 10.1093/jac/30.1.17.J Antimicrob Chemother. 1992.PMID:1331018
- Mechanism of inhibition of the class A beta -lactamases PC1 and TEM-1 by tazobactam. Observation of reaction products by electrospray ionization mass spectrometry.Yang Y, Janota K, Tabei K, Huang N, Siegel MM, Lin YI, Rasmussen BA, Shlaes DM.Yang Y, et al.J Biol Chem. 2000 Sep 1;275(35):26674-82. doi: 10.1074/jbc.M002369200.J Biol Chem. 2000.PMID:10837472
- Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.Lister PD.Lister PD.Pharmacotherapy. 2000 Sep;20(9 Pt 2):213S-218S; discussion 224S-228S. doi: 10.1592/phco.20.14.213s.35045.Pharmacotherapy. 2000.PMID:11001328Review.
- Beta-lactamase inhibitors: evolving compounds for evolving resistance targets.Georgopapadakou NH.Georgopapadakou NH.Expert Opin Investig Drugs. 2004 Oct;13(10):1307-18. doi: 10.1517/13543784.13.10.1307.Expert Opin Investig Drugs. 2004.PMID:15461559Review.
Cited by
- Supramolecular antibiotics: a strategy for conversion of broad-spectrum to narrow-spectrum antibiotics forStaphylococcus aureus.Koyasseril-Yehiya TM, García-Heredia A, Anson F, Rangadurai P, Siegrist MS, Thayumanavan S.Koyasseril-Yehiya TM, et al.Nanoscale. 2020 Oct 22;12(40):20693-20698. doi: 10.1039/d0nr04886k.Nanoscale. 2020.PMID:33029599Free PMC article.
- In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against gram-positive and gram-negative organisms.Jamieson CE, Lambert PA, Simpson IN.Jamieson CE, et al.Antimicrob Agents Chemother. 2003 Aug;47(8):2615-8. doi: 10.1128/AAC.47.8.2615-2618.2003.Antimicrob Agents Chemother. 2003.PMID:12878527Free PMC article.
- Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ.Tamma PD, et al.Clin Infect Dis. 2022 Aug 25;75(2):187-212. doi: 10.1093/cid/ciac268.Clin Infect Dis. 2022.PMID:35439291Free PMC article.
- ESBLs: A Clear and Present Danger?Dhillon RH, Clark J.Dhillon RH, et al.Crit Care Res Pract. 2012;2012:625170. doi: 10.1155/2012/625170. Epub 2011 Jun 6.Crit Care Res Pract. 2012.PMID:21766013Free PMC article.
- Heterogeneity in M. tuberculosis β-lactamase inhibition by Sulbactam.Malla TN, Zielinski K, Aldama L, Bajt S, Feliz D, Hayes B, Hunter M, Kupitz C, Lisova S, Knoska J, Martin-Garcia JM, Mariani V, Pandey S, Poudyal I, Sierra RG, Tolstikova A, Yefanov O, Yoon CH, Ourmazd A, Fromme P, Schwander P, Barty A, Chapman HN, Stojkovic EA, Batyuk A, Boutet S, Phillips GN Jr, Pollack L, Schmidt M.Malla TN, et al.Nat Commun. 2023 Sep 7;14(1):5507. doi: 10.1038/s41467-023-41246-1.Nat Commun. 2023.PMID:37679343Free PMC article.
References
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous